Synthetic biology: at the crossroads of genetic engineering and human therapeutics—a Keystone Symposia report
Year: 2021
Type: article
Abstract: Synthetic biology has the potential to transform cell- and gene-based therapies for a variety of diseases. Sophisticated tools are now available for both eukaryotic and prokaryotic cells to engineer cells to selectively achieve therapeutic effects in response to one or more disease-related signals, thus sparing healthy tissue from potentially cytotoxic effects. This report summarizes the Keystone eSymposium "Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics," which took place on May 3 and 4, 2021. Given that several therapies engineered using synthetic biology have entered clinical trials, there was a clear need for a synthetic biology symposium that emphasizes the therapeutic applications of synthetic biology as opposed to the technical aspects. Presenters discussed the use of synthetic biology to improve T cell, gene, and viral therapies, to engineer probiotics, and to expand upon existing modalities and functions of cell-based therapies.
DOI: 10.1111/nyas.14710
Authors: Jennifer Cable, Joshua N. Leonard, Timothy K. Lu, Zhen Xie, Matthew Wook Chang, Luis Ángel Fernández, José M. Lora, Howard L. Kaufman, Francisco J. Quintana, Roger Geiger, Cammie F. Lesser, Jason P. Lynch, David L. Hava, Virginia W. Cornish, Gary K. Lee, Breanna DiAndreth, Michael Fero, Rajkamal Srivastava, Tim De Coster, Kole T. Roybal, Owen J. L. Rackham, Samira Kiani, Iowis Zhu, Rogelio A. Hernandez‐Lopez, Tingxi Guo, William C. W. Chen
Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chemistry of Life Processes Institute, Massachusetts Institute of Technology, Beijing National Research Center for Information Science and Technology, Tsinghua University, National University of Singapore, Consejo Superior de Investigaciones Científicas, Centro Nacional de Biotecnología, Massachusetts General Hospital, Broad Institute, Brigham and Women's Hospital, Harvard University, Institute of Oncology Research, Institute for Research in Biomedicine, Università della Svizzera italiana, Columbia University, TeselaGen Biotechnology (United States), Saha Institute of Nuclear Physics, Homi Bhabha National Institute, Leiden University Medical Center, University of California, San Francisco, Parker Institute for Cancer Immunotherapy, UCSF Helen Diller Family Comprehensive Cancer Center, Duke-NUS Medical School, University of Pittsburgh
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3214345079